Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Diffuse Large B-Cell Lymphoma Excellence Forum

Diffuse Large B-Cell Lymphoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Dr Burke
Videos
Dr Burke Highlights POLARIX Study on Pola-R-CHP vs R-CHOP for Patients With DLBCL
12/22/2021
John Burke, MD, discusses the phase 3 POLARIX study on pola-R-CHP versus R-CHOP for patients with previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the phase 3 POLARIX study on pola-R-CHP versus R-CHOP for patients with previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the...
12/22/2021
Oncology
Dr Burke
Videos
Dr Burke Discusses Umbralisib and Ublituximab Plus Bendamustine for Patients With R/R DLBCL
12/22/2021
John Burke, MD, discusses the efficacy and safety of umbralisib, ublituximab, and bendamustine for patients with R/R DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the efficacy and safety of umbralisib, ublituximab, and bendamustine for patients with R/R DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the...
12/22/2021
Oncology
dr k
Videos
Dr Kannan Highlights Subasumstat Plus Rituximab for CD20+ R/R NHL, Including DLBCL
12/16/2021
Karuppiah Kannan, PhD, highlights subasumstat in combination with rituximab for CD20+ R/R NHL, including DLBCL, and more. These data were presented at the 2021 ASH Annual Meeting.
Karuppiah Kannan, PhD, highlights subasumstat in combination with rituximab for CD20+ R/R NHL, including DLBCL, and more. These data were presented at the 2021 ASH Annual Meeting.
Karuppiah Kannan, PhD,...
12/16/2021
Oncology
dr C
Videos
Loncastuximab Teserine Plus Ibrutinib Shows Encouraging Anti-Tumor Activity in Patients With R/R DLBCL
12/15/2021
Carmelo Carlo-Stella, MD, discusses a phase 2 study on loncastuximab tesirine plus ibrutinib for patients with advanced DLBCL. These data were presented at the 2021 ASH Annual Meeting.
Carmelo Carlo-Stella, MD, discusses a phase 2 study on loncastuximab tesirine plus ibrutinib for patients with advanced DLBCL. These data were presented at the 2021 ASH Annual Meeting.
Carmelo Carlo-Stella, MD,...
12/15/2021
Oncology
Researchers Discuss Combo Therapy for B-Cell Lymphomas
Videos
Researchers Discuss Combo Therapy for B-Cell Lymphomas
06/02/2021
Alex Herrera, MD, and Amitkumar Mehta, MD, discuss the safety and activity of ibrutinib in combination with durvalumab for B-cell lymphomas.
Alex Herrera, MD, and Amitkumar Mehta, MD, discuss the safety and activity of ibrutinib in combination with durvalumab for B-cell lymphomas.
Alex Herrera, MD, and Amitkumar...
06/02/2021
Oncology
Sattva S. Neelapu, MD, Talks Safety and Efficacy of ALLO-501/647 for Patients With LBCL
Videos
Sattva S. Neelapu, MD, Talks Safety and Efficacy of ALLO-501/647 for Patients With LBCL
09/20/2020
Dr Neelapu talks about early findings from the ALPHA study which suggest that ALLO-501 and ALLO-647 are safe and may be effective in LBCL.
Dr Neelapu talks about early findings from the ALPHA study which suggest that ALLO-501 and ALLO-647 are safe and may be effective in LBCL.
Dr Neelapu talks about early...
09/20/2020
Oncology
CAR T-Cell Therapy Promising for Relapsed/Refractory Large B-Cell NHL
Podcasts
CAR T-Cell Therapy Promising for Relapsed/Refractory Large B-Cell NHL
08/05/2020
Nilanjan Ghosh, MD, reviews results from a pilot study of lisocabtagene maraleucel for the treatment of relapsed large cell lymphomas.
Nilanjan Ghosh, MD, reviews results from a pilot study of lisocabtagene maraleucel for the treatment of relapsed large cell lymphomas.
Nilanjan Ghosh, MD, reviews...
08/05/2020
Oncology
Pallawi Torka, MD, Discusses Outcomes of Patients With Limited-Stage Aggressive LBCL
Videos
Pallawi Torka, MD, Discusses Outcomes of Patients With Limited-Stage Aggressive LBCL
07/22/2020
Dr Torka talks about the outcomes of patients with limited-stage, aggressive large B-cell lymphoma and high-risk cytogenetics.
Dr Torka talks about the outcomes of patients with limited-stage, aggressive large B-cell lymphoma and high-risk cytogenetics.
Dr Torka talks about the...
07/22/2020
Oncology
Bone Marrow Biopsy Histology Impacts Outcomes in FL, DLBCL
Videos
Bone Marrow Biopsy Histology Impacts Outcomes in FL, DLBCL
07/21/2020
Sarah Rutherford, MD, discusses how postinduction bone marrow biopsy histology minimally affects radiographically-defined responses in patients with FL and DLBCL.
Sarah Rutherford, MD, discusses how postinduction bone marrow biopsy histology minimally affects radiographically-defined responses in patients with FL and DLBCL.
Sarah Rutherford, MD, discusses...
07/21/2020
Oncology
Recommended Phase 2 Dosing of Venetoclax Plus DA-EPOCH-R for B-Cell Lymphomas
Videos
Recommended Phase 2 Dosing of Venetoclax Plus DA-EPOCH-R for B-Cell Lymphomas
07/08/2020
Sarah Rutherford, MD, discusses the results from a phase 1 study, which evaluated the combination of venetoclax and DA-EPOCH-R for aggressive B-cell lymphomas.
Sarah Rutherford, MD, discusses the results from a phase 1 study, which evaluated the combination of venetoclax and DA-EPOCH-R for aggressive B-cell lymphomas.
Sarah Rutherford, MD, discusses...
07/08/2020
Oncology

Advertisement

Recent Stories

Jeremy Abramson, MD
Conference Coverage
Glofitamab Plus Gemcitabine and Oxaliplatin Demonstrates Benefit for Patients With R/R Diffuse Large B-Cell Lymphoma
06/27/2024
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data...
06/27/2024
Oncology
Matthew Matasar, MD
Conference Coverage
Odronextamab Demonstrates Efficacy, Safety for Heavily Pretreated Patients With DLBCL Progressing After CAR T-Cell Therapy
06/26/2024
Matthew Matasar, MD, shares data from the 2024 EHA Congress on the ELM-1 study, in which odronextamab monotherapy demonstrated efficacy and safety among pretreated patients with DLBCL who progressed after CAR T-cell therapy.
Matthew Matasar, MD, shares data from the 2024 EHA Congress on the ELM-1 study, in which odronextamab monotherapy demonstrated efficacy and safety among pretreated patients with DLBCL who progressed after CAR T-cell therapy.
Matthew Matasar, MD, shares data...
06/26/2024
Oncology
Matthew Matasar, MD
Conference Coverage
Evaluating the Efficacy of Odronextamab Plus CHOP vs R-CHOP Among Patients With Previously Untreated DLBCL
06/11/2024

Featuring Matthew Matasar, MD

Featuring Matthew Matasar, MD
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses...
06/11/2024
Oncology
David Andorsky, MD, Rocky Mountain Cancer Centers
Videos
Significance of Patient Enrollment in Lymphoma Clinical Trials, Particularly Among Older Patients
06/04/2024

Featuring David Andorsky, MD

Featuring David Andorsky, MD
David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.
David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.
David Andorsky, MD, shares...
06/04/2024
Oncology
Sam Yamshon, MD, Weill Cornell Medicine
Conference Coverage
Safety of CAR T-Cell Therapy Following FDA Warning on Risk of Secondary Malignancies Following Treatment
05/06/2024

Featuring Sam Yamshon, MD

Featuring Sam Yamshon, MD
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the...
05/06/2024
Oncology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement